RT Journal Article
T1 CRISPR/Cas9 in Chronic Lymphocytic Leukemia
A1 Hernández Sánchez, María
AB Genome-editing systems such as Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 technology have uncovered new opportunities to model diseases such as chronic lymphocytic leukemia. CRISPR/Cas9 is an important means of advancing functional studies of Chronic Lymphocytic Leukemia (CLL) through the incorporation, elimination and modification of somatic mutations in CLL models.
PB MPDI
SN 2673-8392
YR 2022
FD 2022-05-27
LK https://hdl.handle.net/20.500.14352/72090
UL https://hdl.handle.net/20.500.14352/72090
LA eng
NO Instituto de Salud Carlos III (ISCIII)/ FEDER
DS Docta Complutense
RD 6 abr 2025